Facebook Linkedin Twitter
Inside Precision Medicine Modified Tree Bark Compound Targets AML

Biopharmaceuticals

Acute myeloid leukemia
News & Features

Modified Tree Bark Compound Targets AML

Chris Anderson -
0
The Current State of Companion Diagnostics in Oncology—A Strategy Review
Molecular Dx

The Current State of Companion Diagnostics in Oncology—A Strategy Review

Kathy Vuksanaj -
0
Black cancer patient
News & Features

New Clinical Trial Recruitment Tools Promises to Bolster Community-Based Research Opportunities

Chris Anderson -
0
Cancer cells, illustration
News & Features

Illumina’s TruSight Test in EU Gets Companion Dx Indication  

Malorye Branca -
0
Can Our Success with HIV Serve as a Guide for Antiviral Drug Development for Covid-19?
Coronavirus

Can Our Success with HIV Serve as a Guide for Antiviral Drug Development for Covid-19?

Kathy Vuksanaj -
0
Two medical doctors shaking hands
Molecular Dx

Interpace Diagnostics, Genecast Join Forces for Translational Studies, Clinical Trials Services

Chris Anderson -
0
UK Joins Biopharmas, Wellcome on £200M Project to Complete UK Biobank Sequencing
Molecular Dx

UK Joins Biopharmas, Wellcome on £200M Project to Complete UK Biobank Sequencing

Alex Philippidis -
0
Medical doctor touching virtual interface button of healthcare application
Informatics

Syapse, Pfizer Ink Real-World Data Precision Oncology Collaboration

Chris Anderson -
0
Interpace Diagnostics Buys Cancer Genetics’ BioPharma Business for $23.5M
Molecular Dx

Interpace Diagnostics Buys Cancer Genetics’ BioPharma Business for $23.5M

Alex Philippidis -
0
Epic Sciences is partnering with four Canadian breast cancer centers to carry out a clinical validation trial of the company’s blood test
Molecular Dx

Epic Sciences, Four Canadian Breast Cancer Centers Launch Trial of Blood Test

Inside Precision Medicine Staff Writer -
0
123Page 2 of 3

Related Content

Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.
Inside Precision Medicine